Cognition Therapeutics’ (CGTX) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report published on Friday morning,Benzinga reports. They currently have a $11.00 price objective on the stock.

A number of other brokerages also recently commented on CGTX. B. Riley restated a “neutral” rating and set a $1.00 price objective (down from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Cantor Fitzgerald cut shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Cognition Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Cognition Therapeutics Stock Down 9.9 %

Shares of NASDAQ CGTX opened at $0.46 on Friday. The firm’s 50-day moving average price is $0.50 and its two-hundred day moving average price is $1.20. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The stock has a market capitalization of $19.16 million, a P/E ratio of -0.48 and a beta of 1.34.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently made changes to their positions in CGTX. Bangor Savings Bank raised its holdings in Cognition Therapeutics by 41.6% during the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after purchasing an additional 10,000 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares in the last quarter. CM Management LLC lifted its holdings in shares of Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after buying an additional 25,000 shares during the period. Sigma Planning Corp boosted its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. Finally, Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics during the first quarter worth about $47,000. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.